<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00247169</url>
  </required_header>
  <id_info>
    <org_study_id>UFK-HEF 4</org_study_id>
    <nct_id>NCT00247169</nct_id>
  </id_info>
  <brief_title>Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II</brief_title>
  <official_title>Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      The investigators want to test whether treatment with a natural progesterone intravaginally&#xD;
      increases the cure rate of cervical intraepithelial neoplasia grade I and II.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        1. The development of cervical intraepithelial neoplasia (CIN) was linked to a decreased&#xD;
           local immune response as evidenced by a decrease of Langerhans' cell (LC) count in the&#xD;
           cervical epithelium. Preliminary studies show that vaginally administered progesterone&#xD;
           locally increases the number of LCs.&#xD;
&#xD;
        2. There is no accepted treatment strategy of low grade CIN, i.e., CIN I and II, than await&#xD;
           spontaneous regression.&#xD;
&#xD;
      Thus, vaginal progesterone is expected to increase the regression rate of cervical dysplasia&#xD;
      grade I and II.&#xD;
&#xD;
      Outcome parameters:&#xD;
&#xD;
      Primary outcome parameters:&#xD;
&#xD;
      To evaluate whether or not a treatment with vaginal progesterone increases regression and&#xD;
      remission rates of CIN I and II during a 6-month treatment period.&#xD;
&#xD;
      Secondary outcome parameters:&#xD;
&#xD;
      Change of immunohistochemically detected expression of LCs in CIN.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Prospective phase II trial with vaginal progesterone as treatment of CIN I and II. 60&#xD;
      patients receive vaginal micronized progesterone 400mg 1x daily for 10 days/month from&#xD;
      menstrual cycle day 16-25 for 6 months. After 3 and 6 months patients are examined for&#xD;
      possible regression, persistence, or progression of disease and treated accordingly.&#xD;
      Treatment of patients with progressing CIN is being discontinued after 3 months. Follow-up of&#xD;
      patients is ensured based on current clinical practice, i.e., regular outpatient visits every&#xD;
      3 months, until the lesion completely regresses.&#xD;
&#xD;
      Diagnosis and main inclusion criteria:&#xD;
&#xD;
      CIN I and II diagnosed by punch biopsy, lesion fully visible, otherwise healthy subjects &lt; 60&#xD;
      years, no history of breast cancer, patient's compliance&#xD;
&#xD;
      Medication:&#xD;
&#xD;
      Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25&#xD;
&#xD;
      Duration of treatment:&#xD;
&#xD;
      6 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether or not a treatment with vaginal progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25 for 6 months increases regression rates of CIN I and II.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of immunohistochemically detected expression of Langerhans Cells in CIN</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological evidence of CIN I and II&#xD;
&#xD;
          2. Transformation zone and lesion margins fully visible&#xD;
&#xD;
          3. Compliant subject&#xD;
&#xD;
          4. Safe contraception&#xD;
&#xD;
          5. Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Lesion related&#xD;
&#xD;
          1. CIN III, (micro)-Invasive Cancer&#xD;
&#xD;
          2. Endocervical lesion, upper margin of lesion not visible on colposcopy&#xD;
&#xD;
          3. Non-compliance of patient&#xD;
&#xD;
          4. PAP V&#xD;
&#xD;
        Drug related&#xD;
&#xD;
          1. Age &gt; 60&#xD;
&#xD;
          2. Hypersensitivity to progesterone or any component of the formulation&#xD;
&#xD;
          3. Thrombophlebitis&#xD;
&#xD;
          4. Undiagnosed vaginal bleeding&#xD;
&#xD;
          5. Carcinoma of the breast&#xD;
&#xD;
          6. Cerebral apoplexy&#xD;
&#xD;
          7. Severe liver dysfunction&#xD;
&#xD;
          8. Pregnancy&#xD;
&#xD;
          9. Depression&#xD;
&#xD;
         10. Diabetes&#xD;
&#xD;
         11. Epilepsy&#xD;
&#xD;
         12. Migraine&#xD;
&#xD;
         13. Renal dysfunction&#xD;
&#xD;
         14. Asthma&#xD;
&#xD;
         15. HIV infection&#xD;
&#xD;
         16. Hepatitis B or C&#xD;
&#xD;
         17. Concurrent use of anticoagulants&#xD;
&#xD;
         18. Uncontrolled hypertension (&gt; 160/90 mmHg)&#xD;
&#xD;
         19. Breast cancer in personal history&#xD;
&#xD;
         20. Concurrent hormonal therapy including OC&#xD;
&#xD;
        Clinical laboratory related&#xD;
&#xD;
          1. Hemoglobin &lt; 11 g/dl&#xD;
&#xD;
          2. Leukocytes &lt; 4,0 x 109/L&#xD;
&#xD;
          3. Platelet count &lt; 100 x 109/L&#xD;
&#xD;
          4. Serum bilirubin &gt; 2 x above upper cut-off value&#xD;
&#xD;
          5. Serum GOT &gt; 2 x above upper cut-off value&#xD;
&#xD;
          6. Serum GPT &gt; 2 x above upper cut-off value&#xD;
&#xD;
          7. Serum alkaline phosphatase &gt; 2 x above upper cut-off value&#xD;
&#xD;
          8. Serum creatinine &gt; 2 x above cut-off value&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas A Hefler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept OB/GYN, Med University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 31, 2005</study_first_submitted>
  <study_first_submitted_qc>October 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2005</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>LHefler</investigator_full_name>
    <investigator_title>Assoc Professor</investigator_title>
  </responsible_party>
  <keyword>cervical intraepithelial neoplasia (CIN)</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

